治疗心血管系统疾病的内皮素抑制剂研究进展  

Endothelin inhibitors for cardiovascular diseases

作　　者：赵金龙[1] 周志旭[1] 吴成军[1] 柳蓓蓓[1] 孙铁民[1] 

机构地区：[1]沈阳药科大学基于靶点的药物设计与研究教育部重点实验室,沈阳110016

出　　处：《中南药学》2014年第1期37-43,共7页Central South Pharmacy

摘　　要：心血管疾病是威胁人类健康的头号杀手,发病机制有多种。其中内皮素是迄今为止发现的最强的缩血管多肽,其缩血管作用是AngⅡ的10倍,是肾上腺素的100倍,此外还有细胞增殖和组织纤维化等作用,对高血压、肺动脉高压、动脉粥样硬化、心律失常等心血管疾病的发病机制有着重要影响。从发现内皮素到现在二十多年来,药学工作者对内皮素受体拮抗剂进行了一系列的研究,一些内皮素受体拮抗剂已经上市用于肺动脉高压等心血管疾病的治疗。Cardiovascular disease is a leading killer to human health with many kinds of pathogenesis. Among them, endothelin is the strongest vasoconstrictive polypeptide. It＇s vessel shrinking role was 10 times stronger than that of Ang Ⅱ, and 100 times that of adrenaline. In addition, endothelin also has some effects on the cell proliferation and tissue fibrosis. Endothelin plays an important role in the pathogenesis of hypertension, pulmonary hypertension, ath- erosclerosis, arrhythmia and so on. In the last 20 years after the discovery of endothelin, a series of researches have been conducted by pharmacists. Some endothelin receplor antagonists have been listed for the treatment of pulmonary hypertension and other cardiovascular diseases.

关 键 词：内皮素受体拮抗剂 肺动脉高压 高血压 内皮素 

分 类 号：R972[医药卫生—药品]